PERCUTANEOUS INTERVENTION AND RENAL DYSFUNCTION
Impact of mild or moderate chronic kidney disease on the frequency of restenosis
Results from the PRESTO trial
Patricia J.M. Best, MD*,*,
Peter B. Berger, MD ,
Barry R. Davis, MD, PhD ,
Cindy L. Grines, MD ,
H. Mehrdad Sadeghi, MD ,
Brent A. Williams, MS*,
James T. Willerson, MD||,
Jeffrey R. Granett, MD¶,
David R. Holmes, Jr, MD* PRESTO Investigators
* Mayo Clinic, Rochester, Minnesota, USA
Duke University, Durham, North Carolina, USA
University of Texas School of Public Health, Houston, Texas, USA
William Beaumont Hospital, Royal Oak, Michigan, USA
|| University of Texas Medical School and Texas Heart Institute, Houston, Texas, USA
¶ GlaxoSmithKline, Collegeville, Pennsylvania, USA
Manuscript received February 20, 2004;
revised manuscript received July 6, 2004,
accepted July 12, 2004.
* Reprint requests and correspondence: Dr. Patricia J. M. Best, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905 (Email: best.patiricia{at}mayo.edu).
OBJECTIVES: The goal of this study was to determine if restenosis is increased in mild and moderate chronic kidney disease (CKD) patients after percutaneous coronary intervention (PCI).
BACKGROUND: Mortality is increased in CKD after PCI. Restenosis may contribute to increased late mortality.
METHODS: We analyzed 11,187 patients with a creatinine <1.8 mg/dl from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial, grouped by estimated creatinine clearance (CrCl) (<60, 60 to 89, >89 ml/min). The Cox proportional hazards models investigated the association between CrCl group and death, myocardial infarction, and target vessel revascularization (TVR). Generalized estimating equation regression models determined the association between CrCl group and lesion-specific restenosis.
RESULTS: At 30 days, there was no difference in myocardial infarction, death, or TVR between the CrCl groups. At nine months, mortality was higher in the lowest CrCl group (2.2%, 1.2%, 0.8%; p < 0.001), which was no longer significant after adjusting for confounding variables. Myocardial infarction and TVR were not different between the groups. In patients undergoing protocol follow-up angiography, restenosis ( 50%) was not increased with CKD (32%, 32%, 37%; p = 0.02).
CONCLUSIONS: Mortality nine months after PCI is mildly increased in mild or moderate CKD patients. However, restenosis is not and does not account for the increased mortality.
|
Abbreviations and Acronyms
| | CABG = coronary artery bypass graft | | CHF = congestive heart failure | | CKD = chronic kidney disease | | CrCl = creatinine clearance | | HR = hazard ratio | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | PRESTO = Prevention of REStenosis with Tranilast and its Outcomes trial | | TVR = target vessel revascularization |
|
This article has been cited by other articles:

|
 |

|
 |
 
C. E. Appleby, J. Ivanov, S. Lavi, K. Mackie, E. M. Horlick, D. Ing, C. B. Overgaard, P. H. Seidelin, R. von Harsdorf, and V. Dzavik
The Adverse Long-Term Impact of Renal Impairment in Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stent Era
Circ Cardiovasc Interv,
August 1, 2009;
2(4):
309 - 316.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. H. Lopes, F. da Silva Paulitsch, A. Pereira, C. L. Garzillo, J. F. Ferreira, N. Stolf, and W. Hueb
Mild chronic kidney dysfunction and treatment strategies for stable coronary artery disease.
J. Thorac. Cardiovasc. Surg.,
June 1, 2009;
137(6):
1443 - 1449.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Charytan, L. Wallentin, B. Lagerqvist, R. Spacek, R. J. De Winter, N. M. Stern, E. Braunwald, C. P. Cannon, and N. K. Choudhry
Early Angiography in Patients with Chronic Kidney Disease: A Collaborative Systematic Review
Clin. J. Am. Soc. Nephrol.,
June 1, 2009;
4(6):
1032 - 1043.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Manzano-Fernandez, F. Marin, F. J. Pastor-Perez, C. Caro, F. Cambronero, J. Lacunza, E. Pinar, D. A. Pascual-Figal, M. Valdes, and G. Y. H. Lip
Impact of Chronic Kidney Disease on Major Bleeding Complications and Mortality in Patients With Indication for Oral Anticoagulation Undergoing Coronary Stenting
Chest,
April 1, 2009;
135(4):
983 - 990.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Charytan, J. P. Forman, and D. E. Cutlip
Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease
Nephrol. Dial. Transplant.,
September 1, 2007;
22(9):
2578 - 2585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Hillis, B. H. Cuthbertson, and B. L. Croal
Renal function, revascularization and risk
Eur. Heart J.,
April 1, 2007;
28(7):
782 - 784.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N.C. Edwards, R.P. Steeds, C.J. Ferro, and J.N. Townend
The treatment of coronary artery disease in patients with chronic kidney disease
QJM,
November 1, 2006;
99(11):
723 - 736.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|